Pegunigalsidase alfa not checked

Chiesi Farmaceutici S.p.A. · Protalix · PRX-102

FollowEvery change as it happens, and a Monday email
Stage
in the US
Next date
Phase 2/3 trial completes
Trials
2 active
8 in total · 2 in the EU
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
Tested for
Fabry Disease (2 trials)
Main trialPhase 2/3
“The aim of this study is to evaluate the safety and efficacy of pegunigalsidase alfa in Japanese patients (adults and adolescents) affected by Fabry disease. It is planned of a total of approximately 16 male and female Fabry disease patients between the ages of 13 and 70 years to be part of the study. The study is conducted in Japan.”In the company’s words, NCT05710692 on ClinicalTrials.gov
Other names
PRX-102 · Recombinant human alpha galactosidase-A

Other drugs for Fabry Disease

All 9 drugs for Fabry Disease

Coming up2

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials8

TrialPhaseCompletesWhat it tests
Phase 2/3Recruiting Oct 2027 Study to Evaluate the Safety, PK, PD, and Efficacy of PRX-102 in Japanese Patients With Fabry Disease
Phase 2/3Recruiting Oct 2028 A Study to Learn About the Safety and Effects of the Study Drug PRX-102 in Children and Adolescents With Fabry Disease
Phase 3Completed 17 Dec 2019 Safety and Efficacy of PRX-102 in Patients With Fabry Disease Currently Treated With REPLAGAL® (Agalsidase Alfa)
Phase 3Completed Oct 2021 Study of the Safety and Efficacy of PRX-102 Compared to Agalsidase Beta on Renal Function
Phase 3Completed 21 Jan 2025 Open Label Extension Study of 1 mg/kg Pegunigalsidase Alfa Every 2 Weeks in Patients With Fabry Disease
Phase 3Completed 13 Apr 2026 Open Label Extension of 2 mg/kg Pegunigalsidase Alfa (PRX-102) Every 4 Weeks in Adult Fabry Disease Patients
Phase 1/2Completed 6 Mar 2016 Dose-ranging Study of PRX-102 in Adult Fabry Disease Patients
Phase 1/2Completed 26 Aug 2020 Extension Study of PRX-102 for up to 60 Months
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow Pegunigalsidase alfa

Following is part of Solo: you see every change to Pegunigalsidase alfa the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in